# A Study to Evaluate the Safety and Tolerability of Long-Acting Oral Risperidone (LYN-005) in Participants With Schizophrenia or Schizoaffective Disorder

> **NCT06878833** · PHASE3 · WITHDRAWN · sponsor: **Lyndra Inc.**

## Conditions studied

- Schizophrenia
- Schizoaffective Disorder

## Interventions

- **DRUG:** LYN-005 (risperidone)
- **DRUG:** Placebo for LYN-005
- **DRUG:** IR Risperidone
- **DRUG:** Placebo for IR Risperidone

## Key facts

- **NCT ID:** NCT06878833
- **Lead sponsor:** Lyndra Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-04-18
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor stopped operations
- **Last updated:** 2025-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06878833

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06878833, "A Study to Evaluate the Safety and Tolerability of Long-Acting Oral Risperidone (LYN-005) in Participants With Schizophrenia or Schizoaffective Disorder". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06878833. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*